Lite Strategy, Inc. (LITS)
1.14
+0.10
(+9.62%)
USD |
NASDAQ |
Sep 04, 16:00
1.14
0.00 (0.00%)
After-Hours: 20:00
Lite Strategy Research and Development Expense (Quarterly) : 0.03M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 0.03M |
| December 31, 2025 | 0.046M |
| September 30, 2025 | 0.01M |
| June 30, 2025 | 0.083M |
| March 31, 2025 | 0.369M |
| December 31, 2024 | 0.308M |
| September 30, 2024 | 3.163M |
| June 30, 2024 | 3.944M |
| March 31, 2024 | 5.22M |
| December 31, 2023 | 3.912M |
| September 30, 2023 | 3.485M |
| June 30, 2023 | 2.57M |
| March 31, 2023 | 15.10M |
| December 31, 2022 | 15.31M |
| September 30, 2022 | 19.46M |
| June 30, 2022 | 21.84M |
| March 31, 2022 | 22.32M |
| December 31, 2021 | 21.53M |
| September 30, 2021 | 19.95M |
| June 30, 2021 | 16.29M |
| March 31, 2021 | 17.88M |
| December 31, 2020 | 22.22M |
| September 30, 2020 | 13.00M |
| June 30, 2020 | 7.859M |
| March 31, 2020 | 8.963M |
| Date | Value |
|---|---|
| December 31, 2019 | 8.281M |
| September 30, 2019 | 8.962M |
| June 30, 2019 | 8.032M |
| March 31, 2019 | 9.071M |
| December 31, 2018 | 9.066M |
| September 30, 2018 | 6.131M |
| June 30, 2018 | 4.459M |
| March 31, 2018 | 3.071M |
| December 31, 2017 | 3.444M |
| September 30, 2017 | 6.064M |
| June 30, 2017 | 2.073M |
| March 31, 2017 | 1.876M |
| December 31, 2016 | 1.642M |
| September 30, 2016 | 1.646M |
| June 30, 2016 | 3.985M |
| March 31, 2016 | 3.42M |
| December 31, 2015 | 3.182M |
| September 30, 2015 | 2.816M |
| June 30, 2015 | 3.779M |
| March 31, 2015 | 6.775M |
| December 31, 2014 | 6.703M |
| September 30, 2014 | 6.566M |
| June 30, 2014 | 6.413M |
| March 31, 2014 | 5.415M |
| December 31, 2013 | 4.40M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| SELLAS Life Sciences Group, Inc. | 6.272M |
| ACADIA Pharmaceuticals, Inc. | 81.56M |
| Alnylam Pharmaceuticals, Inc. | 413.13M |
| Anika Therapeutics, Inc. | 7.341M |
| Savara, Inc. | 21.95M |